In the phase Ia DLBCL expansion, the median maximum fold change in gene expression from baseline superseded the predesignated twofold or greater change from baseline for both HIST2H2BF and CCR2. HEXIM1 also superseded twofold or greater change from baseline at 2.0 mg but not at 1.5 mg or 2.5 mg (Figure 2). The gene discussed is CCR2; the disease is diffuse large B-cell lymphoma.